0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Diastolic Heart Failure"

Following a topic allows Research and Markets to customize your experience and provide personalized recommendations.
From
EUR$3,545USDGBP
EUR$3,939USDGBP
Congestive Heart Failure (CHF) Market Report 2025 - Product Thumbnail Image

Congestive Heart Failure (CHF) Market Report 2025

  • Report
  • April 2025
  • 175 Pages
  • Global
From
EUR$4,490USDGBP
EUR$211USDGBP
EUR$207USDGBP
EUR$170USDGBP
  • 8 Results (Page 1 of 1)
Loading Indicator

Diastolic heart failure is a type of heart failure in which the heart's left ventricle is unable to fill with enough blood during diastole, the period of relaxation between heartbeats. This can lead to a decrease in cardiac output, resulting in symptoms such as shortness of breath, fatigue, and swelling of the legs and feet. Treatment for diastolic heart failure typically involves lifestyle modifications such as reducing salt intake, quitting smoking, and exercising regularly. Medications such as diuretics, ACE inhibitors, and beta-blockers may also be prescribed to reduce symptoms and improve quality of life. Companies in the diastolic heart failure market include AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Merck & Co., Novartis, Pfizer, Sanofi, and Takeda. Show Less Read more

This website uses cookies to ensure you get the best experience. Learn more